Bardin Stephen

CFO Bardin Stephen bought 2,000 shares of CALC at $1.50 on 2025-06-26, doubling holdings to 3,000 shares amid -73.3% 52-week decline.

CFO Bardin Stephen purchased 2,000 shares at $1.50, increasing his total holdings from 1,000 to 3,000 shares in a company trading at $1.43—near its 52-week low of $1.43 after a -73.3% decline from the $5.35 high. The company reported net income of $-5,042,000.00 over its most recent full fiscal year and carries a market cap of $19,979,945.70, indicating a small-cap biomedical firm under significant financial stress. This represents the CFO's second open-market purchase at CALC within a month (prior buy on 2025-05-30), but timing context on the first purchase remains unmeasurable. The concentrated purchase near absolute lows in a loss-making entity warrants monitoring of whether this reflects access to non-public positive developments or simply illiquidity in a distressed position.

CFO Bardin buys 1,000 shares of CALC at $1.69; stock now -71.4% from 52-week high amid ongoing losses.

CFO Stephen Bardin purchased 1,000 shares at $1.69 on 2025-05-30, bringing his holdings to 41,000 shares. The transaction occurred when CalciMedica's stock is trading at $1.63, down 71.4% from its 52-week high of $5.69 and has declined 23.5% over the past 90 days. The company reported a net income of $-5.0M over its most recent full fiscal year, indicating ongoing unprofitability. The buy occurs in an environment of significant stock depreciation and negative fundamentals, but without visibility into Bardin's stated rationale or scheduling (10b5-1 plan status, etc.), the transaction itself represents a small addition to holdings rather than a material confidence signal.